Chairman: Dr. Wilco Tanis
Infective endocarditis (IE) carries a substantial morbidity and mortality risk with an in-hospital mortality of 15-20%). This primarily stems from the risk of severe complications, including sepsis, thromboembolisms, heart failure, and local peri-annular extension of the infection. In order to improve endocarditis care and mortality rates in the Netherlands, adequate evaluation of diagnostics, treatment strategies and outcome is needed. In addition, solid nationwide collaboration is crucial. Therefore, in 2022 the working group for IE in the Netherlands ENDOCOR (analogous to CONCOR) was developed.
At the forefront of the ENDOCOR initiative is the goal to significantly decrease the morbidity and mortality associated with endocarditis. To achieve this, ENDOCOR will promote collaboration among the multidisciplinary endocarditis teams across the country, it will function as a platform for the exchange of knowledge and expertise, and organise nationwide education. In addition, ENDOCOR aims to reinforce national research efforts, which includes the establishment of a national registration for all IE patients in collaboration with the Netherlands Heart Registration (NHR).
The NHR enables the use of real-world data to monitor and further improve the quality of care of cardiovascular diseases. There is an existing nationwide cardiothoracic registry of the NHR of patients with endocarditis, however this registry lacks microbiological, antibiotic and imaging data and most important, only consist of surgically treated endocarditis patients. Therefore, the new endocarditis registration will cover a wider range of relevant IE topics and incorporate all IE patients, regardless of whether they undergo surgical treatment or not. In January 2023, a pilot project for this registry was initiated across three selected centers and easily accessible and shareable data registration lists were developed for different electronic patient records (HiX and Epic included) as well. Anticipated in 2024, the registration is set to launch across all participating hospitals in the Netherlands. This NHR endocarditis registry is a voluntary registration. The primary objective is to ensure quality control; which, in case of significant variation in the findings, will facilitate discussions regarding the different diagnostic and treatment strategies in a safe setting. In addition, this large-scale and long-term prospectively collected data will offer unique insights in epidemiological changes and temporal trends of IE in the Netherlands. Moreover, in the future, it will be easier to retrospectively gather additional information about any remarkable subgroups within the IE cohort.
In conclusion, the ENDOCOR consortium aims to unite healthcare professionals, organise education, establish a national registry and reinforce nationwide impactful research. With these proactive and collaborative efforts ENDOCOR strives to significantly decrease the morbidity and mortality associated with endocarditis.